1nhaler Ltd

Cover Block

Name	1nhaler Ltd
Tagline	Cardboard pop-up single-dose dry powder inhaler for drug delivery
Headquarters	Edinburgh, Scotland
Founded	2017
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Seed (total disclosed ~$4,400,000)

Links

• Website: https://www.1nhaler.com/home-1
• LinkedIn: https://www.linkedin.com/company/1nhaler
• X / Twitter: https://twitter.com/1nhaler

The Short Version

1nhaler Ltd is developing a single-dose dry powder inhaler made from flat, credit-card-sized cardboard that folds into a three-dimensional device, aiming to offer pharmaceutical partners a low-cost, low-carbon alternative to traditional plastic inhalers [Archangels, 2024]. The company, founded in Edinburgh in 2017 by Don Smith and Lisa McMyn, has raised approximately $4.4 million in seed funding across three rounds led by Archangels, with support from Scottish Enterprise and BBB Investments [UK Tech News, Nov 2023] [Finsmes, Nov 2025]. Its propellant-free platform uses a proprietary membrane dispersion technology designed to support a variety of dry-powder medicines, targeting inhaled therapies for conditions from asthma and COPD to epilepsy and Parkinson's [Archangels, 2024].

The founding team has been bolstered by key appointments from major pharmaceutical companies, including Chief Scientific Officer Helen Muirhead, who led development of GSK's Diskus and Ellipta inhalers, and Board Chair Jane Gaddum, a former AstraZeneca marketing executive [Archangels, 2024]. The business model is exclusively B2B, positioning 1nhaler as a drug-delivery device partner for pharma and biotech companies seeking to develop or reformulate drugs for inhalation. Capital raised is being deployed to advance the platform toward a first Marketing Authorisation Application targeted for late 2027, which involves manufacturing clinical material and designing commercial-scale processes [Scottish Enterprise].

Over the next 12-18 months, the primary milestones to watch are progress in regulatory studies and the securing of a first named pharmaceutical development partnership, which would serve as a critical validation signal for the platform's technical and commercial feasibility.

Data Accuracy: YELLOW -- Core company description and funding totals are corroborated by multiple investor releases; team backgrounds and product claims are primarily sourced from a single investor publication.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	Western Europe
Founding Team	Co-Founders (2)
Funding	Seed (total disclosed ~$4,400,000)

The Company in Brief

1nhaler Ltd was incorporated in Edinburgh, Scotland, on August 11, 2017, by co-founders Don Smith and Lisa McMyn [GOV.UK]. The company operates as a drug delivery device developer, maintaining its registered office and headquarters in Edinburgh [GOV.UK] [1nhaler]. The founding narrative centers on developing a low-cost, sustainable alternative to traditional plastic inhalers, with the core concept of a flat, credit-card-sized device that folds into a three-dimensional inhaler emerging from this period [Archangels, 2024].

Key corporate milestones have unfolded through a series of seed funding rounds led by the Scottish angel syndicate Archangels. An initial raise of £2 million (approximately $2.5 million) was secured in 2023 to advance device development [UK Tech News, Nov 2023]. This was followed by an additional £1.5 million in seed funding, announced in 2024, with continued participation from Scottish Enterprise and BBB Investments [Scottish Enterprise]. The capital has been earmarked to progress the platform technology toward a first Marketing Authorisation Application (MAA), targeted for late 2027 [Archangels, 2024].

A significant milestone in 2023 was the assembly of a leadership team with deep pharmaceutical industry credentials. The company appointed Helen Muirhead, formerly Head of the Respiratory Centre of Excellence at GSK with development responsibility for the Diskus and Ellipta inhalers, as Chief Scientific Officer [Archangels, 2024]. In 2024, Jane Gaddum, a former Vice President for global marketing emerging brands at AstraZeneca, joined as Board Chair and Non-Executive Director [Archangels, 2024]. These appointments signal a strategic build-out of regulatory and commercial expertise ahead of clinical trials.

Data Accuracy: GREEN -- Company incorporation and headquarters confirmed by GOV.UK and company website. Funding rounds and leadership appointments corroborated by multiple investor and news sources.

What They Have Built

1nhaler's platform is a single-dose dry powder inhaler made predominantly from cardboard that folds from a flat, credit-card-sized form into a 3D inhaler for single-dose delivery [Archangels, 2024]. The technology is propellant-free, using a proprietary 'membrane dispersion technology' to deliver a variety of medicines in dry-powder format [Archangels, 2024]. Target therapeutic areas include asthma, COPD, influenza, anaphylaxis, epilepsy, depression, and Parkinson's [Archangels, 2024].

The company has engaged with Upperton Pharma Solutions for clinical trial material and Harro Höfliger for the design of commercial-scale manufacturing processes [Scottish Enterprise, 2024] [HARRO, 2022]. The near-term goal is to advance the platform towards a first Marketing Authorisation Application (MAA) targeted for late 2027 [Scottish Enterprise, 2024].

Data Accuracy: YELLOW -- Core product claims are consistent across investor releases, but detailed technical specifications and independent performance data are not publicly available.

Market Size and Demand

Metric	Value
Respiratory Drug Delivery Devices Market (2021)	$34.5B
Projected Market (2028)	$52.7B

Data Accuracy: YELLOW -- Market sizing is based on an analogous third-party report for the broader category; specific DPI platform TAM is not publicly quantified by the company or its investors.

Who Else Is Fighting for This

Company	Positioning	Stage / Funding	Notable Differentiator
1nhaler Ltd	Single-dose, pop-up cardboard DPI platform for pharma partners	Seed, ~$4.4M total (2023-2025)	Low-cost, low-carbon, propellant-free, credit-card-sized flat form factor
MannKind Corp	Commercial-stage developer of inhalable insulin and other drugs using its Technosphere dry-powder delivery platform	Public (NASDAQ: MNKD), $1.3B market cap (Apr 2025)	Proprietary formulation technology enabling rapid absorption of large molecules like insulin
OptiNose	Commercial-stage developer of nasal delivery devices and therapeutics (e.g., Xhance)	Public (NASDAQ: OPTN), ~$200M market cap (Apr 2025)	Bi-directional nasal delivery technology designed to target deep nasal passages
Impel NeuroPharma	Commercial-stage developer of precision olfactory delivery (POD) devices for migraine and CNS disorders	Public (NASDAQ: IMPL), ~$50M market cap (Apr 2025)	Device designed to deliver drugs through the upper nasal cavity to the brain

Data Accuracy: YELLOW -- Competitor profiles and funding are public, but 1nhaler's specific competitive advantages are based on company and investor claims.

Opportunity

Scenario	What happens	Catalyst	Why it's plausible
Respiratory Anchor	The device becomes the preferred platform for next-generation rescue or short-course respiratory drugs (e.g., for asthma, COPD, influenza).	A development partnership with a mid-to-large pharma company to co-develop a specific drug-device combination.	The team's deep respiratory expertise from GSK and AstraZeneca provides credibility and network access in this core market [Archangels, 2024].
CNS Breakthrough	The platform enables a novel, inhaled formulation for a central nervous system disorder (e.g., epilepsy, depression), creating a new category of rapid-acting treatments.	Successful completion of a Phase I/II clinical trial for a partnered CNS drug, demonstrating proof-of-concept for systemic delivery via the cardboard device.	The company explicitly lists epilepsy and depression as target therapeutic areas, indicating active exploration beyond respiratory [Archangels, 2024].
Sustainability Mandate	Environmental regulations or payer pressure on plastic waste in healthcare drive widespread adoption of the low-carbon device as a replacement for existing single-use plastic inhalers.	A major public healthcare system (e.g., NHS) issues a tender or guideline favoring sustainable medical devices.	The company's materials and environmental claims are a central part of its public narrative and investor messaging [Scottish Enterprise, 2024] [Daily Business, Nov 2025].

Data Accuracy: YELLOW -- Opportunity scenarios are extrapolated from company and investor statements; market comparable is publicly available.

Analyst Notes

Verdict: WATCH, The company is pre-commercial and relies on securing a first pharmaceutical partnership to validate its platform. Conviction: Moderate Time horizon: 12-18 months

Agentic / AI relevance

1nhaler's platform is a physical device, not an AI-driven software product. Its relevance to AI is limited to potential future applications in digital health, such as integrating smart-packaging or adherence-tracking sensors into the cardboard device, though no such plans are currently disclosed.

Sources

1. [Archangels, 2024] 1nhaler appoints pharma industry leaders to board and secures funding to advance innovative inhaler platform | https://www.archangelsonline.com/news/1nhaler-appoints-pharma-industry-leaders-to-board-and-secures-funding-to-advance-innovative-inhaler-platform
2. [UK Tech News, Nov 2023] Scottish startup raises £2m for single-use inhaler | https://www.uktech.news/medtech/1nhaler-single-use-inhaler-20231127
3. [Finsmes, Nov 2025] 1nhaler Raises £1.5M in Funding | https://www.finsmes.com/2025/11/1nhaler-raises-1-5m-in-funding.html
4. [Scottish Enterprise] 1nhaler hires pharma industry leaders for key roles ahead of clinical trials | https://www.scottish-enterprise-mediacentre.com/news/1nhaler-hires-pharma-industry-leaders-for-key-roles-ahead-of-clinical-trials
5. [GOV.UK] 1NHALER LTD overview | https://find-and-update.company-information.service.gov.uk/company/SC573454
6. [1nhaler] About | https://www.1nhaler.com/home-1
7. [HARRO, 2022] 1nhaler - Passion and patience | https://www.harro-magazine.com/en/13-2022/1nhaler-passion-and-patience/
8. [Fortune Business Insights] Respiratory Drug Delivery Devices Market Size, Share & Industry Analysis | https://www.fortunebusinessinsights.com/respiratory-drug-delivery-devices-market-105175
9. [MannKind, 2025] MannKind Corporation Investor Relations | https://investor.mannkindcorp.com/
10. [OptiNose, 2025] OptiNose Investor Relations | https://investors.optinose.com/
11. [Impel NeuroPharma, 2025] Impel NeuroPharma Investor Relations | https://investors.impelnp.com/
12. [Public financials, 2025] Public market data for MannKind Corp | https://finance.yahoo.com/quote/MNKD/
13. [Daily Business, Nov 2025] Funding support for novel eco-friendly inhaler | https://dailybusinessgroup.co.uk/2025/11/funding-support-for-novel-eco-friendly-inhaler/